Rizzi CA - Search Results

1

Italian validation of the urogenital distress inventory and its application in LUTS patients.

Artibani W, Pesce F, Prezioso D, Scarpa RM, Zattoni F, Tubaro A, Rizzi CA, Santini AM, Simoni L; FLOW study group. Artibani W, et al. Among authors: rizzi ca. Eur Urol. 2006 Dec;50(6):1323-9. doi: 10.1016/j.eururo.2006.04.008. Epub 2006 May 4. Eur Urol. 2006. PMID: 16713067

2

Italian validation of the International Consultation on Incontinence Questionnaires.

Tubaro A, Zattoni F, Prezioso D, Scarpa RM, Pesce F, Rizzi CA, Santini AM, Simoni L, Artibani W; Flow Study Group. Tubaro A, et al. Among authors: rizzi ca. BJU Int. 2006 Jan;97(1):101-8. doi: 10.1111/j.1464-410X.2006.05885.x. BJU Int. 2006. PMID: 16336337

3

Aims and methods. LUTS suggestive of BPH.

Prezioso D, Scarpa RM, Zattoni F, Viaggi S, Termini R, Berioli S, Rizzi CA. Prezioso D, et al. Among authors: rizzi ca. Eur Urol. 2001;40 Suppl 1:2-4. doi: 10.1159/000049869. Eur Urol. 2001. PMID: 11598345

4

Home and office uroflowmetry for evaluation of LUTS from benign prostatic enlargement.

Porru D, Scarpa RM, Prezioso D, Bertaccini A, Rizzi CA; HOUSE Study Group. Porru D, et al. Among authors: rizzi ca. Prostate Cancer Prostatic Dis. 2005;8(1):45-9. doi: 10.1038/sj.pcan.4500763. Prostate Cancer Prostatic Dis. 2005. PMID: 15655566 Clinical Trial.

5

A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA; MICTUS Study Group. Rigatti P, et al. Among authors: rizzi ca. Prostate Cancer Prostatic Dis. 2003;6(4):315-23. doi: 10.1038/sj.pcan.4500680. Prostate Cancer Prostatic Dis. 2003. PMID: 14663474 Clinical Trial.

6

Pharmacological properties of a novel class of 5-HT3 receptor antagonists.

Turconi M, Donetti A, Schiavone A, Sagrada A, Montagna E, Nicola M, Cesana R, Rizzi C, Micheletti R. Turconi M, et al. Eur J Pharmacol. 1991 Oct 15;203(2):203-11. doi: 10.1016/0014-2999(91)90716-4. Eur J Pharmacol. 1991. PMID: 1800117

7

Characterization of FR 172357, a new non-peptide bradykinin B(2) receptor antagonist, in human, pig and rabbit preparations.

Rizzi C, Rizzi A, Calò G, Jorizzo G, Agnello G, Mollica G, Inamura N, Regoli D. Rizzi C, et al. Eur J Pharmacol. 1999 Dec 10;386(1):25-31. doi: 10.1016/s0014-2999(99)00711-6. Eur J Pharmacol. 1999. PMID: 10611460

8

Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors.

Rizzi CA, Sagrada A, Schiavone A, Schiantarelli P, Cesana R, Schiavi GB, Ladinsky H, Donetti A. Rizzi CA, et al. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. doi: 10.1007/BF00170878. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 8058105

9

Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285.

Dumuis A, Gozlan H, Sebben M, Ansanay H, Rizzi CA, Turconi M, Monferini E, Giraldo E, Schiantarelli P, Ladinsky H, et al. Dumuis A, et al. Among authors: rizzi ca. Naunyn Schmiedebergs Arch Pharmacol. 1992 Mar;345(3):264-9. doi: 10.1007/BF00168685. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1320204

10

Benzimidazolone derivatives: a new class of 5-hydroxytryptamine4 receptor agonists with prokinetic and acetylcholine releasing properties in the guinea pig ileum.

Rizzi CA, Coccini T, Onori L, Manzo L, Tonini M. Rizzi CA, et al. J Pharmacol Exp Ther. 1992 May;261(2):412-9. J Pharmacol Exp Ther. 1992. PMID: 1578356

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters